STOCK TITAN

Invitation - Presentation of Sobi's Q3 2020 results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

On October 22, 2020, at 08:00 CET, Swedish Orphan Biovitrum AB (Sobi™) will release its Q3 2020 report. A teleconference, hosted by CEO Guido Oelkers, will follow at 13:00 CEST for investors and media. The event will be accessible live and thereafter on Sobi's website. Sobi focuses on rare diseases, employing around 1,400 staff across multiple regions. In 2019, Sobi reported a revenue of SEK 14.2 billion. Further details can be found on Sobi’s website.

Positive
  • Scheduled release of Q3 2020 report indicates proactive communication with investors.
  • Company's focus on rare diseases positions it well in a specialized market.
  • 2019 revenue of SEK 14.2 billion demonstrates strong financial performance.
Negative
  • None.

STOCKHOLM, Oct. 7, 2020 /PRNewswire/ -- On 22 October, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2020. Investors, financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 13:00 CEST. The event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held in English.

The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.

To participate in the telephone conference, please call:

SE: +46-8-566-42-705

UK: +44-333-300-90-32

US: +1-646-722-49-02

Click here to go to the live webcast.

After the live event the webcast will be available on-demand via the same link.

About Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenue amounted to SEK 14.2 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

For more information please contact

Paula Treutiger, Head of Communication & Investor Relations
+46-733-666-599
paula.treutiger@sobi.com

Linda Holmström, Corporate Communication & Investor Relations
+46-708-734-095
linda.holmstrom@sobi.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation---presentation-of-sobi-s-q3-2020-results,c3211454

The following files are available for download:

https://mb.cision.com/Main/14266/3211454/1315667.pdf

Invitation to presentation of Q3 2020 report

 

Cision View original content:http://www.prnewswire.com/news-releases/invitation--presentation-of-sobis-q3-2020-results-301147384.html

SOURCE Swedish Orphan Biovitrum AB

FAQ

What date will Sobi publish its Q3 2020 results?

Sobi will publish its Q3 2020 results on October 22, 2020.

What time is Sobi's Q3 2020 teleconference?

The teleconference for Sobi's Q3 2020 results will be held at 13:00 CEST.

Who will present Sobi's Q3 2020 results?

Sobi's Q3 2020 results will be presented by CEO Guido Oelkers.

Where can I find Sobi's Q3 2020 presentation?

The Q3 2020 presentation can be accessed live and on-demand on Sobi's website.

What revenue did Sobi report in 2019?

Sobi reported a revenue of SEK 14.2 billion in 2019.

SWEDISH ORPHAN BIOVIT ORD

OTC:BIOVF

BIOVF Rankings

BIOVF Latest News

BIOVF Stock Data

8.50B
184.75M
10.08%
73.48%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Solna